US Reclassifies Medical Marijuana
Analysis based on 12 articles · First reported Apr 23, 2026 · Last updated Apr 23, 2026
The reclassification of medical marijuana to Schedule III by the United States — United States Department of Justice is expected to significantly boost the cannabis industry by providing major tax breaks to state-licensed medical marijuana operators and easing research barriers. This move is likely to positively impact publicly traded cannabis companies and related pharmaceutical entities, potentially leading to increased investment and market growth in the sector.
President Donald Trump's administration, through acting attorney general Todd Blanche, reclassified state-licensed medical marijuana from Schedule I to Schedule III. This policy shift, long sought by advocates, does not legalize marijuana federally but changes its regulation, offering significant tax breaks to licensed medical marijuana operators and easing research barriers. The United States — United States Department of Justice is also initiating a broader reclassification process. While welcomed by the American Trade Association for Cannabis and Hemp, the move drew criticism from Kevin Sabet of Smart Approaches to Marijuana, who called it a 'tax break to Big Weed'. This action legitimizes medical marijuana programs in 40 states and represents a major federal policy change.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard